Owkin Stock

AI Medical Research Testing

Sign up today and learn more about Owkin Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About Owkin Stock

Owkin is a startup that provides machine learning that allows medical researchers to test AI models on distributed data. The company deploys AI and federated learning for medical research and aims to empower researchers in hospitals, universities, and pharmaceutical companies to understand why drug efficacy varies from patient to patient, enhance the drug development process, and identify the best drug for the right patient to improve treatment outcomes. It is backed by investors such as F-Prime Capital & Eight Roads Ventures, GV, Otium Ventures, Cathay Innovation, and NJF Capital as well as a scientific board. It was co-founded in 2016 by Thomas Clozel, a hematologist oncologist and researcher, and Gilles Wainrib, a computer science teacher-researcher in New York, New York.


Funding History

October 2016$2.1M
January 2018$11.0M
May 2018$5.0M
March 2019$13.0M
May 2020$25.0M
July 2020$18.0M


Chief Executive Officer

Thomas Clozel


alleywatch - Jan, 21 2018

#NYCtech Week in Review

pehub - Jan, 17 2018

Owkin lands $11 mln Series A

EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.

Some data provided by Crunchbase

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As: